Aim: We aimed to clarify post-prandial accumulation of remnant-like particles (RLP) in patients with sitosterolemia.

Methods: Oral fat tolerance test cream (Jomo Shokuhin, Takasaki, Japan) 50 g was given per body surface area (m²); blood sampling was performed at 2 h intervals up to 6 h. Plasma lipoprotein fractions and RLP fractions were determined in four sitosterolemic subjects with double mutations in ATP-binding cassette (ABC) sub-family G member 5 or member 8 (ABCG5 or ABCG8) gene (mean age 18 yr, median low-density lipoprotein cholesterol [LDL-C] = 154 mg/dL), six heterozygous carriers (mean age 31 yr, median LDL-C = 105 mg/dL), and five subjects with heterozygous familial hypercholesterolemia (FH, mean age 32 yr, median LDL-C = 221 mg/dL). The incremental area under curve (iAUC) of lipids, including LDL-C, apolipoprotein B-48 (apoB48), RLP cholesterol (RLP-C), and RLP triglyceride (RLP-TG) were evaluated.

Results: After oral fat load, there was no significant difference of the iAUC of LDL-C between sitosterolemia and heterozygous FH, whereas the iAUC of apoB48 was significantly larger in the sitosterolemic subjects compared with that of heterozygous FH (2.9 µg/mL·h vs. 1.3 µg/mL·h, p < 0.05). Under these conditions, the iAUCs of RLP-C and RLP-TG levels were significantly larger in the sitosterolemic subject compared with those of heterozygous FH (9.5 mg/dL·h vs. 5.7 mg/dL·h, p < 0.05; 149 mg/dL·h vs. 40 mg/dL·h, p < 0.05, respectively), whereas those of heterozygous carriers were comparable with those with heterozygous FH.

Conclusions: Post-prandial lipoprotein metabolism in sitosterolemia appeared to be impaired, leading to their elevation in serum sterol levels. (UMIN Clinical Trials Registry number, UMIN000020330)

Key words: Sitosterolemia, Remnant, Familial hypercholesterolemia, Remnant-like-particles, OFTT

Introduction

Familial hypercholesterolemia (FH) is a common inherited disorder of plasma lipoprotein metabolism, characterized by an elevated level of low-density lipoprotein cholesterol (LDL-C), tendon xanthomas, and premature coronary artery disease. Monogenic causes of FH involve gene mutations such as LDL receptor, apolipoprotein B-100 (apoB100), and proprotein convertase subtilisin/kexin type 9 (PCSK9). Post-prandial accumulation of lipoprotein remnants has been shown to be related with elevated cardiovascular risk. Under these conditions, it has been shown that post-prandial lipoprotein metabolism is severely impaired in a dominant form of FH, whereas we have shown that such lipoprotein metabolism is preserved in a recessive form of FH called autosomal recessive hypercholesterolemia caused by mutations in LDL receptor adaptor protein 1 (LDLRAP1) gene. Investigating the extreme cases harboring mutations in a specific gene provides an opportunity to directly observe the role of certain molecules in lipoprotein metabolism.

Sitosterolemia (OMIM #210250) is a rare, inherited, autosomal recessive disorder of lipid metabolism

Copyright © 2018 Japan Atherosclerosis Society
This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.
ers with single mutation, and heterozygous FH are enrolled in this study. They receive an oral fat tolerance test (OFTT) cream when they met the inclusion criteria. We then compare post-prandial plasma RLP cholesterol (RLP-C) levels between the patients with sitosterolemia with double mutations in \textit{ABCG5} or \textit{ABCG8} gene, heterozygous mutation carriers with single mutation, and heterozygous FH. This study has been registered at the University Hospital Medical Information Network (UMIN) (UMIN ID: 000020330)\textsuperscript{10}).

**Study Subjects**

Four patients with sitosterolemia harboring double mutations in \textit{ABCG5} or \textit{ABCG8} gene, six relatives with a heterozygous mutation, and five unrelated subjects with heterozygous FH were enrolled in this study. None of the subjects had taken medication known to affect plasma lipids for at least 4 weeks before this study was conducted. None had smoking habits and excessive alcohol intake (> ethanol 60 g/day).

**Materials and Methods**

**Study Design**

This study is a single-arm, non-randomized, open-label, uncontrolled trial. Patients with homozygous sitosterolemia with double mutations, heterozygous carriers with single mutation, and heterozygous FH are enrolled in this study. They receive an oral fat tolerance test (OFTT) cream when they met the inclusion criteria. We then compare post-prandial plasma RLP cholesterol (RLP-C) levels between the patients with sitosterolemia with double mutations in \textit{ABCG5} or \textit{ABCG8} gene, heterozygous mutation carriers with single mutation, and heterozygous FH. This study has been registered at the University Hospital Medical Information Network (UMIN) (UMIN ID: 000020330)\textsuperscript{10}).
for triglyceride (TG), LDL-C, apoB48, sitosterol, RLP-C, and RLP triglyceride (RLP-TG) at baseline and after fat load were calculated using the trapezoid rule. The differences in the incremental AUC (iAUC) of the plasma variables between the three groups were examined using Kruskal–Wallis test. Post hoc analyses using Scheffé’s method were performed when the main effect was significant. All tests of statistical significance were assumed at a level of \( p < 0.05 \).

**Ethical Considerations**

This study was approved by the Ethics Committee of Kanazawa University and carried out in accordance with the Declaration of Helsinki (2008) of the World Medical Association. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (insti-

**Statistical Analysis**

Values are expressed as medians (interquartile [IQR]) unless otherwise stated. Area under curve (AUC) and 

**Fig. 1.** Line charts of lipoproteins

Bars indicate standard errors.
Red: Sitosterolemia
Pink: Single mutation carrier
Light blue: Heterozygous FH
tutional and national) and with the Declaration of Helsinki of 1975, as revised in 2008. Informed consents were obtained from all subjects for being included in the study.

**Results**

The baseline characteristics of the three study groups are shown in Table 1. Genetic backgrounds of the study subjects are shown in Supplemental Table 1. These groups of patients were comparable in terms of age, gender, and body mass index (BMI). Interestingly, the baseline LDL-C level of sitosterolemic patients with double mutations was significantly higher than that of single mutation, whereas baseline LDL-C level of heterozygous FH was significantly higher than that in sitosterolemic subjects. On the other hand, serum levels of sitosterol and campesterol in sitosterolemic patients with double mutations were significantly higher than those with a single mutation as well as those in heterozygous FH. In addition, apoB48, TG, RLP-C, and RLP-TG levels were significantly higher in sitosterolemic subjects than those in heterozygous FH (Table 1).

After oral fat load, lipoproteins, other than LDL-C, increased through 2 to 4 h (Figs. 1 and 2). There was no significant difference in the iAUC of LDL-C between sitosterolemia and heterozygous FH, whereas the iAUC of TG was significantly larger in sitosterolemic subjects that in heterozygous FH (154 mg/dL χ h vs. 50 mg/dL χ h, p < 0.05, Fig. 3).

Interestingly, the iAUC of apoB48 was significantly larger in the sitosterolemic subjects compared with that of heterozygous FH (2.9 µg/mL χ h vs. 1.3 µg/mL χ h, p < 0.05, Fig. 3). In addition to those results, the iAUC of sitosterol in the sitosterolemic subjects was significantly larger than that of heterozygous FH as expected (66 µg/mL χ h vs. 0.5 µg/mL χ h, p < 0.05). Under these conditions, the iAUCs of RLP-C and RLP-TG levels were significantly larger in the sitosterolemic subjects compared with those of heterozygous FH (9.5 mg/dL χ h vs. 5.7 mg/dL χ h, p < 0.05; 149 mg/dL χ h vs. 40 mg/dL χ h, p < 0.05, respectively, Fig. 4), whereas those of single mutation carrier in ABCG5 or ABCG8 gene were comparable with those with heterozygous FH.

**Discussion**

The main finding of the present study is that the clearance of post-prandial RLP fraction was impaired in sitosterolemia compared with heterozygous FH. This is the first study to demonstrate the impaired post-prandial RLP metabolism in sitosterolemia.

Impaired TG-rich lipoprotein metabolism under the condition of disturbance of ABCG5/ABCG8 have been implicated by the observational and interventional studies of sitosterolemic subjects\(^{14,15}\) as well as by the experimental study using ABCG5/ABCG8 knockout
been shown to be associated with atherosclerotic cardiovascular diseases\(^\text{18}\), was significantly elevated in sitosterolemic patients both in fasting state, as well as in post-prandial state. In addition, we observed that the peaks of the post-prandial lipoproteins were earlier in sitosterolemic patients than those in heterozygous FH. Moreover, sitosterol level in sitosterolemic patients increased after fat load, although such trends were not observed in heterozygous FH nor in single mutation carriers. Thus, dietary counseling for the patients with sitosterolemia should be one of the reasonable approaches for their risk management.

In this study, we compared post-prandial lipoprotein metabolism in sitosterolemia with that in heterozygous FH mice (sitosterolemic mice)\(^\text{16}\). Previously, we demonstrated that breastfed infantile cases with sitosterolemia harboring double mutations in \(ABCG5\) gene exhibit transient extreme hyper-LDL cholesterolemia\(^\text{19}\). In addition, there have been great diversities in the LDL-C levels among the subjects with sitosterolemia described so far\(^\text{17}\). Such observations as well as the facts that \(ABCG5/ABCG8\) are playing an important role in excretion of sterols in the intestine could lead us to investigate if the patients with sitosterolemia harboring \(ABCG5/ABCG8\) mutations are vulnerable to diet-induced hyperlipidemia. We confirmed that post-prandial RLP metabolism was disturbed in the patients with sitosterolemia for the first time. Moreover, apoB48 level, which has been shown to be associated with atherosclerotic cardiovascular diseases\(^\text{18}\), was significantly elevated in sitosterolemic patients both in fasting state, as well as in post-prandial state. In addition, we observed that the peaks of the post-prandial lipoproteins were earlier in sitosterolemic patients than those in heterozygous FH. Moreover, sitosterol level in sitosterolemic patients increased after fat load, although such trends were not observed in heterozygous FH nor in single mutation carriers. Thus, dietary counseling for the patients with sitosterolemia should be one of the reasonable approaches for their risk management.

In this study, we compared post-prandial lipoprotein metabolism in sitosterolemia with that in heterozygous FH mice.
zygous FH, not with normal controls. It is well known that the patients with sitosterolemia exhibit dyslipidemia, including elevation of LDL-C. And RLP-C has been shown to be correlated with LDL-C, especially in cases with elevated LDL-C\(^{19}\). Accordingly, it is rather fair to compare sitosterolemia and heterozygous FH under the condition of elevated LDL-C in both sides.

This study has several limitations. First, only a small number of subjects were included in this study. It is difficult to enroll more sitosterolemic patients because of the rarity of this disorder. However, our subjects were comparatively uniform in terms of factors potentially affecting the post-prandial lipoprotein metabolism—age, sex, and BMI—among study subjects. Second, we used OFTT cream without plant sterols making it difficult to see the effect on such sterols in this study. However, loading sitosterol on sitosterolemia are considered ethically unacceptable, although the increased plant sterols themselves may not relate with atherosclerosis\(^{20,21}\). Third, TG level was significantly higher in sitosterolemia than in other two groups. In this regard, it has been shown that fasting TG level was significantly associated with post-prandial lipemia\(^{22}\). Accordingly, our results may not be reflected by actual "post-prandial" lipemia itself. Despite those limitations, we believe that this study provides new insights into the roles of \(ABC\) in the post-prandial lipoprotein metabolism.

### Acknowledgements and Notice of Grant Support

We express our special thanks to Kazuko Honda and Sachio Yamamoto (staff of Kanazawa University) for their outstanding technical assistance. We also express our special thanks to Drs. Takuya Nakahashi, Yoshito Tanaka, Taro Ichise, Takashi Kobayashi, Azusa Obbatake, and Akari Wada for their assistance in data collection. We have received the research grants from Sakakibara Memorial Research Grant from the Japan Research Promotion Society for Cardiovascular Diseases and Astellas Foundation for Research on Metabolic Disorders.

### COI

Hayato Tada has received a research grant from Sanofi K.K. Atsushi Nohara and Hiroshi Mabuchi have received research grants from MSD K.K., Sanofi K.K., Shionogi & Co., Ltd., Kowa Co., Ltd., Astellas Pharma Inc., AstraZeneca K.K., Keiai-Kai Medical Corp., and Biopharm of Japan Co. Masakazu Yamagishi has received research grants from MSD K.K., Astellas Pharma Inc., Daiichi-Sankyo Co., Ltd., and Otsuka Pharmaceutical.

---

Fig. 4. The iAUC of RLP fractions

Boxplots illustrating the iAUC of (A) RLP-C and (B) RLP-TG in three groups.
Red: Sitosterolemia
Pink: Single mutation carrier
Light blue: Heterozygous FH
Co., Ltd., and he has received payments for lectures from Astellas Pharma Inc., Daiichi-Sankyo Co., Ltd., Shionogi & Co., Ltd., and Kowa Co., Ltd. Masa-aki Kawashiri has received payments for lectures from Amgen Astellas Biopharma K.K. and Astellas Pharma Inc.

References


### Supplemental Table 1. Genetic backgrounds of the subjects

<table>
<thead>
<tr>
<th>Sitosterolemia</th>
<th>Heterozygous carrier</th>
<th>Heterozygous FH</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n = 4)</td>
<td>(n = 6)</td>
<td>(n = 5)</td>
</tr>
<tr>
<td>c.1256G &gt; A/c.1763-1G &gt; A (ABCG5)</td>
<td>c.1256G &gt; A (ABCG5)</td>
<td>c.1702C &gt; G (LDLR)</td>
</tr>
<tr>
<td>c.454C &gt; T/c.1403_1404delTC (ABCG8)</td>
<td>c.1763-1G &gt; A (ABCG5)</td>
<td>c.1845 + 2T &gt; C (LDLR)</td>
</tr>
<tr>
<td>c.1306G &gt; A/c.1813_1817delCTTTT (ABCG5)</td>
<td>c.1306G &gt; A (ABCG5)</td>
<td>c.2054C &gt; T (LDLR)</td>
</tr>
<tr>
<td>c.130T &gt; G/c.1306G &gt; A (ABCG5)</td>
<td>c.1813_1817delCTTTT (ABCG5)</td>
<td>c.2431A &gt; T (LDLR)</td>
</tr>
<tr>
<td></td>
<td>c.1306G &gt; A (ABCG5)</td>
<td>c.94G &gt; A (PCSK9)</td>
</tr>
<tr>
<td></td>
<td>c.130T &gt; G</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(ABCG5)</td>
<td></td>
</tr>
</tbody>
</table>

FH: familial hypercholesterolemia, ABCG5: ATP-binding cassette (ABC) sub-family G member 5, ABCG8: ATP-binding cassette (ABC) sub-family G member 8, LDLR: low-density lipoprotein receptor, PCSK9: proprotein convertase subtilisin/kexin type 9